Mobile Health Intervention to Improve Exercise in Pediatric PH

Not Applicable

Recruiting

• Conditions: Pulmonary Arterial Hypertension
• Interventions: Device: mHealth Intervention; Device: Usual Care

• Registration Number: NCT06549452
• Lead Sponsor: Vanderbilt University Medical Center

Brief Summary

Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations. In adults, investigators recently demonstrated that lower baseline daily step counts associated with increased risk of hospitalization and worsening WHO functional class; similarly, reduced step counts associate with hospitalization in children with PAH. This application builds on our recently completed NIH-funded pilot mobile health (mHealth) trial in adult patients with PAH which demonstrated the ability to remotely increase step counts. The investigators now aim to: (1) adapt our mHealth intervention to the developmental needs and interests of adolescents; and, (2) determine if our intervention increases step counts in adolescents, providing the foundation for a larger trial to assess the impact on quality of life and clinical outcomes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-06-24
• Study First Submitted QC: 2024-08-07
• Study First Posted: 2024-08-12
• Status Verified: 2024-12
• Study Start: 2024-12-01
• Last Update Submitted: 2024-12-30
• Last Update Posted: 2024-12-31
• Primary Completion: 2028-11-01
• Study Completion: 2030-11-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Adolescents between ages 13-19 years.
• Diagnosed with idiopathic, heritable, or associated (connective tissue disease, drugs, or toxins) pulmonary arterial hypertension (PAH), or PAH due to simple congenital heart disease (i.e. atrial septal defect).
• WHO functional class I-III
• Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.
• Forced vital capacity >65% predicted with no or minimal interstitial lung disease based on reviews of imaging studies by PI and medical monitor.

Read More

Exclusion Criteria

• Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity.
• Pregnancy
• Diagnosis of PAH etiology other than idiopathic, heritable, or associated.
• Functional class IV heart failure
• Requirement of > 2 diuretic adjustment in the prior three months.
• Preferred form of activity is not measured by an activity tracker (swimming, yoga, ice skating, stair master, or activities on wheels such as bicycling or rollerblading).
• Involved in any other investigational intervention.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
mHealth Intervention	mHealth Intervention	Patients will be randomized to the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
Usual Care	Usual Care	Routine medical care

Primary Outcome Measures

Name	Time	Method
Change in average daily step count from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on average daily step count from baseline to 12 weeks.; Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Step counts will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.

Secondary Outcome Measures

Name	Time	Method
Change in Quality of Life as measured by the Short Form 36-Item Health Survey (SF-36)	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on quality of life between baseline and Week 12.; The SF36 is one of the most widely used generic measures of subjective health status. The SF36 includes one multi-item scale that assesses eight health concepts.; Scoring the SF 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per a scoring key. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the low
Difference in unadjusted raw daily steps from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on unadjusted change in raw daily steps from baseline to 12 weeks.; Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Step counts and will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.
Difference in frequency of goal attainment from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on frequency (% days) of goal attainment from baseline to 12 weeks.; Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Frequency (% days) of goal attainment will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.
Difference in Echocardiographic pericardial effusion from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on Echocardiographic pericardial effusion from baseline to 12 weeks.
Time to clinical worsening	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on a composite outcome of PAH-related hospitalization, medication regimen escalation, decrease in vital status, and all-cause mortality at 12 weeks after randomization. Clinical worsening events are defined as death (all causes), hospitalizations due to worsening pulmonary arterial hypertension (PAH), escalation in WHO functional class, and initiation of an inhaled or infused prostacyclin (PGI2) for the treatment of worsening PAH.
Change in Quality of Life as measured by the emPHasis-10	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on quality of life between baseline and Week 12.; The emPHasis-10 is a pulmonary hypertension-specific questionnaire to assess health related quality of life. It covers breathlessness, fatigue and lack of energy, social restrictions, and concerns regarding effects on patient's significant others, such as family and friends. Each item is scored on a semantic differential six-point scale (0-5), with contrasting adjectives at each end. A total emPHasis-10 score is derived using simple aggregation of the 10 items. emPHasis-10 scores range from 0 to 50, higher scores indicate worse quality of life.
Change in Quality of Life as measured by the Pediatric Quality of Life Inventory (PedsQL)	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on quality of life between baseline and Week 12.; The Pediatric Quality of Life Inventory (PedsQL) Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL integrates seamlessly both generic core scales and disease-specific modules into one measurement system, which generally takes about 4 minutes to complete. Each item is scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always), then reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better health-related quality of life.
Change in Quality of Life as measured by the Pediatric Inventory for Parents (PIP)	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on quality of life between baseline and Week 12.; The PIP is a questionnaire comprising 42 items, grouped into four domains or subscales: medical care, communication, emotional functioning, and role function. Its purpose is to measure the levels of stress suffered by parents caring for a child with a chronic disease. Responses are provided using a five-point Likert scale, ranging from 1 ("never/not at all") to 5 ("very often/extremely"). Higher scores indicate higher levels of stress.
Difference in total daily activity from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on total daily activity time from baseline to 12 weeks. Activity time is defined as time spent above 3 metabolic equivalents.; Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Activity time will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.
Difference in total daily aerobic time from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on total daily aerobic time from baseline to 12 weeks. Aerobic time is defined as the total time spent walking continuously for \> 10 minutes without breaking for \> 1 minute.; Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Aerobic time will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.
Difference in mean daily steps during week 12 and week 18	Week 12 & Week 18	To assess the effect of a mHealth intervention or no intervention on mean daily steps during week 12 and week 18.; Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Step counts will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.
Difference in B-type natriuretic peptide levels from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on B-type natriuretic peptide levels (pg/mL) between baseline and 12 weeks.
Difference in 6-Minute walk test distance from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on the 6-minute walk test distance (meters) between baseline and 12 weeks.
Difference in Echocardiographic TAPSE from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on Echocardiographic tricuspid annular plane systolic excursion (TAPSE) from baseline to 12 weeks.
Difference in Echocardiographic EI from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on Echocardiographic eccentricity index (EI) from baseline to 12 weeks.
Difference in Echocardiographic maximal tricuspid regurgitant velocity from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on Echocardiographic maximal tricuspid regurgitant velocity from baseline to 12 weeks.
Difference in Echocardiographic measurement of RV fractional area change (FAC) from baseline to 12 weeks	Baseline to 12 weeks	To assess the effect of a mHealth intervention or no intervention on Echocardiographic measurement of RV fractional area change (FAC) from baseline to 12 weeks.

Trial Locations

Locations (1)

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States